Growth in the dental bone graft substitute market is driven primarily by the increasing prevalence of dental disorders, continuous product commercialization, market availability & product affordability, rising number of geriatric population, and growing public awareness related to preventive care.
According to the latest market research by MarketsandMarkets,” The dental bone graft substitute market size is projected to reach USD 659 million by 2025 from USD 450 million in 2020, at a CAGR of 7.9%.”
Current Market Opportunities:
1. Increasing demand from customers and rising inclination toward cosmetic dentistry
2. Low penetration rates for dental implants
3. Growing demand for bone graft substitutes from emerging markets
Dental Bone Graft Substitute Market Size Estimation:
The study involved four major activities to estimate the current size of the dental bone graft substitute market. Both top-down and bottom-up approaches were used to estimate and validate the total size of the dental bone graft substitute market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
1. The key players in the industry and markets have been identified through extensive secondary research.
2. The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research.
Download PDF Brochure of Dental Bone Graft Substitute Market Research:
Increasing technological advancements have increased the number of synthetic graft options. The benefits of synthetic grafts include availability, sterility, and reduced morbidity. Also, the synthetic bone grafts have a longer shelf life and there is no risk of any disease to get transferred. Because of these benefits synthetic bone graft is the fastest growing type in the dental bone graft substitutes market.
The synthetic bone graft segment is expected to account for the 22.0% share of the global dental bone graft substitutes market in 2019. IngeniOs from Zimmer Biomet Holdings, Inc. (US) and MASTERGRAFT from BioHorizons IPH, Inc. (US) are some commonly used synthetic bone grafts.
The end-user segment for dental bone graft substitutes market used in hospitals, small clinics, and critical care units. Positive demand growth of dental bone graft substitutes by hospitals are mainly attributed to the advancements in orthodontic treatment and cosmetic dentistry, growing geriatric population and increasing number of cosmetic dentistry procedures. The results of a survey conducted by the American Association of Oral and Maxillofacial Surgeons in the US were as follows:
1. Over 30 million people do not have teeth in one or both jaws
2. 26.0% people aged above 75 years do not have teeth at all
3. 69.0% of people aged between 35 and 45 years have one tooth missing
4. More than 15 million people have crowns or bridges
5. Approximately 500,000 people undergo dental implant procedure each year
6. Dental implants have a success rate of about 95.0%.
Key Questioned Answered in Report:
# Who are the key players in the market and which strategies have they pursued?
# What does the competitive landscape in this market look like?
# What is the strategic analysis of different geographical regions?
# What are the different market opportunities for stakeholders?
Request Sample Report:
Geographical Growth Analysis:
Europe is one of the major revenue-generating regions in the dental bone graft substitute market. The favorable reimbursement & insurance coverage for major procedures and supportive government regulations for product commercialization are the major factors driving the growth of the dental bone graft substitute market in Europe.
Dental Bone Graft Substitute Market Key Players:
Dentsply Sirona (US), Johnson & Johnson (US), Danaher Corporation (US), Medtronic (Ireland), Strauman (US), Zimmer Dental (US), Geistlich Pharm (Switzerland), RTI Surgical (US), BioHorizons, IPH, Inc (US), Dentium (South Korea), LifeSciences Corporation (US), Smith & Nephew (UK), Novabone LLC (US), Botiss biomaterials GmbH (US), Collagen Matrix Inc. (US), Osteogenics Biomedical (US), LifeNet Health (US), Wright Medical (US), and Stryker Corporation (US).
I am a Corporate Communicator where I help companies about the growth of the healthcare market and solve their companies’ growth and research. Reach out to me in case you have something I can help with.